Valencia Living

Valencia Living Assisted Living & Retirement in Avianto Estate. Home Care, Respite Care, 24/7 Care. Affordable cost

𝑽𝒂𝒍𝒆𝒏𝒄𝒊𝒂 𝑨𝒔𝒔𝒊𝒔𝒕𝒆𝒅 𝑳𝒊𝒗𝒊𝒏𝒈 𝒂𝒏𝒅 𝑹𝒆𝒕𝒊𝒓𝒆𝒎𝒆𝒏𝒕 𝑬𝒔𝒕𝒂𝒕𝒆 is operated by MedTech Group which is a leading provider of home care, retirement and residential services, providing quality care and support to families and individuals since 1995. Our team of experienced and dedicated professionals have a wealth of knowledge in the healthcare industry, having a global footprint of staff, owning and operating care f

acilities in the UK, Canada and South Africa. We offer industry-beating competitive pricing and provide 𝐔𝐊 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 𝐜𝐚𝐫𝐞, 𝐭𝐫𝐚𝐢𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐯𝐞𝐭𝐭𝐢𝐧𝐠 to ensure our clients receive the 𝐡𝐢𝐠𝐡𝐞𝐬𝐭 𝐥𝐞𝐯𝐞𝐥 𝐨𝐟 𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐲. Our team members are dedicated to 𝒕𝒓𝒆𝒂𝒕𝒊𝒏𝒈 𝒄𝒍𝒊𝒆𝒏𝒕𝒔 𝒘𝒊𝒕𝒉 𝒄𝒐𝒎𝒑𝒂𝒔𝒔𝒊𝒐𝒏, 𝒓𝒆𝒔𝒑𝒆𝒄𝒕 𝒂𝒏𝒅 𝒅𝒊𝒈𝒏𝒊𝒕𝒚, 𝒘𝒐𝒓𝒌𝒊𝒏𝒈 𝒊𝒏 𝒑𝒆𝒓𝒔𝒐𝒏-𝒄𝒆𝒏𝒕𝒓𝒆𝒅 𝒄𝒂𝒓𝒆 whilst providing the highest quality of service. With over 25 years of experience in the retirement and acquired brain and spinal injury sectors, we are confident in providing an exceptional standard of care to our clients.

29/05/2026
https://www.facebook.com/share/p/1CfMLFQn1n/
29/05/2026

https://www.facebook.com/share/p/1CfMLFQn1n/

Scientists found an enzyme that "eats" arterial plaque.

The discovery by Italian researchers could eventually replace open-heart surgery.

An elite research network across Italy has isolated a specific class of specialized bacterial enzymes capable of naturally breaking down the dense, calcified fatty deposits known as arterial plaque. Published in the European Heart Journal, the preclinical study demonstrates how these highly targeted bio-catalysts can selectively degrade the complex fibrin-lipid matrix that forms the structural foundation of atherosclerosis.

Utilizing advanced nanotechnology, scientists engineered biocompatible lipid-shell nanocarriers to encapsulate the enzymes, allowing them to travel through the bloodstream completely undetected by the immune system.

Once these smart carriers encounter the precise inflammatory signals emitted by an obstructed vessel, they release their enzymatic payload directly into the plaque barrier, safely dissolving the mechanical blockage and restoring blood flow without requiring a single invasive incision or stent deployment.

While the prospect of naturally reversing established coronary artery disease represents a historic paradigm shift for cardiovascular medicine, cardiologists emphasize that this biological solution is still moving through its foundational safety pipeline. Replicating the 42% plaque reduction observed in animal models requires absolute precision; if the enzymes are released prematurely or interact with healthy vascular tissues, they risk destabilizing stable arterial walls or triggering major systemic bleeding events. Human clinical safety trials are not projected to begin for several years, meaning that rigorous lifestyle management, statin therapies, and regular cardiovascular screeners remain the definitive gold standard for managing heart health.

Reference

Rossi, M., Bianchi, L., & Ferrero, G. (2026). Nanoparticle-targeted enzymatic degradation of atherosclerotic plaque: An in vivo proof of concept. European Heart Journal, 47(18), 1422-1435.

Address

Plot 69, R114 Driefontein Road
Muldersdrift
1747

Alerts

Be the first to know and let us send you an email when Valencia Living posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Valencia Living:

Share